{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:02:03Z","timestamp":1789768923321,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.dmd.2026.100369","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:19:53Z","timestamp":1784301593000},"page":"100369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel in vitro permeability and efflux classification system for proteolysis targeting chimeras"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2575-8059","authenticated-orcid":false,"given":"Siennah R.","family":"Greenfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0721-7456","authenticated-orcid":false,"given":"Philip","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara P.","family":"Puckett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Crouthamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8961-7522","authenticated-orcid":false,"given":"Chiaowen Joyce","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8480-9645","authenticated-orcid":false,"given":"Hao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.dmd.2026.100369_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.dmd.2026.100369_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103395","article-title":"PROTAC technology: a new drug design for chemical biology with many challenges in drug discovery","volume":"28","author":"Guedeney","year":"2023","journal-title":"Drug Discov Today"},{"issue":"4","key":"10.1016\/j.dmd.2026.100369_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic\u2014a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100369_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103917","article-title":"Exploring the chemical space of orally bioavailable PROTACs","volume":"29","author":"Apprato","year":"2024","journal-title":"Drug Discov Today"},{"issue":"5","key":"10.1016\/j.dmd.2026.100369_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100066","article-title":"Applications of contemporary tools to measure plasma protein binding of targeted protein degraders","volume":"53","author":"Niosi","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"20","key":"10.1016\/j.dmd.2026.100369_bib6","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1039\/c3an01116j","article-title":"Correlation of in vitro and in vivo plasma protein binding using ultracentrifugation and UPLC-tandem mass spectrometry","volume":"138","author":"Srikanth","year":"2013","journal-title":"Analyst"},{"issue":"3","key":"10.1016\/j.dmd.2026.100369_bib7","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0022-3549(15)00177-X","article-title":"Application of cassette ultracentrifugation using non-labeled compounds and liquid chromatography-tandem mass spectrometry analysis for high-throughput protein binding determination","volume":"105","author":"Kieltyka","year":"2016","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.dmd.2026.100369_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.slast.2023.10.008","article-title":"Automated measurement of transepithelial electrical resistance (TEER) in 96-well transwells using ECIS TEER96: single and multiple time point assessments","volume":"29","author":"Schimetz","year":"2024","journal-title":"SLAS Technol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100369_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1113\/expphysiol.1981.sp002529","article-title":"Identification of two strains of cultured canine renal epithelial cells (MDCK cells) which display entirely different physiological properties","volume":"66","author":"Barker","year":"1981","journal-title":"Q J Exp Physiol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100369_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2121-12-43","article-title":"The MDCK variety pack: choosing the right strain","volume":"12","author":"Dukes","year":"2011","journal-title":"BMC Cell Biol"},{"issue":"12","key":"10.1016\/j.dmd.2026.100369_bib11","doi-asserted-by":"crossref","first-page":"8281","DOI":"10.1021\/acs.jmedchem.3c00740","article-title":"Physicochemical property determinants of oral absorption for PROTAC protein degraders","volume":"66","author":"Hornberger","year":"2024","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.dmd.2026.100369_bib12","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1039\/D4MD00854E","article-title":"In vitro and in vivo ADME of heterobifunctional degraders: a tailored approach to optimize DMPK properties of PROTACs","volume":"16","author":"Maurer","year":"2025","journal-title":"RSC Med Chem"},{"issue":"15","key":"10.1016\/j.dmd.2026.100369_bib13","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.1021\/acs.jmedchem.4c01017","article-title":"Structural and physicochemical features of oral PROTACs","volume":"67","author":"Schade","year":"2024","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.dmd.2026.100369_bib14","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3390\/pharmaceutics13081146","article-title":"A bidirectional permeability assay for beyond rule of 5 compounds","volume":"13","author":"Cui","year":"2021","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.dmd.2026.100369_bib15","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/pharmaceutics16070846","article-title":"Conquering the beyond rule of five space with an optimized high-throughput Caco-2 assay to close gaps in absorption prediction","volume":"16","author":"Muschong","year":"2024","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.dmd.2026.100369_bib16","doi-asserted-by":"crossref","first-page":"P738","DOI":"10.1177\/2472555219848483","article-title":"Addition of optimized bovine serum albumin level in a high-throughput Caco-2 assay enabled accurate permeability assessment for lipophilic compounds","volume":"24","author":"Cai","year":"2019","journal-title":"SLAS Discov"},{"issue":"9","key":"10.1016\/j.dmd.2026.100369_bib17","doi-asserted-by":"crossref","first-page":"9584","DOI":"10.1021\/acs.jmedchem.5c00358","article-title":"In vitro ADME profiling of PROTACs: successes, challenges, and lessons learned from analysis of clinical PROTACs from a diverse physicochemical space","volume":"68","author":"Srivastava","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.dmd.2026.100369_bib20","series-title":"Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, Division on Earth and Life Studies, National Research Council. Guide for the Care and Use of Laboratory Animals","year":"2011"},{"issue":"12","key":"10.1016\/j.dmd.2026.100369_bib21","first-page":"3710","article-title":"A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies","volume":"8","author":"Rubin","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dmd.2026.100369_bib22","series-title":"M9 Biopharmaceutics Classification System-Based Biowaivers","year":"2021"},{"issue":"5","key":"10.1016\/j.dmd.2026.100369_bib23","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1021\/acs.molpharmaceut.6b01059","article-title":"In vitro intrinsic permeability: a transporter-independent measure of Caco-2 cell permeability in drug design and development","volume":"14","author":"Fredlund","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.dmd.2026.100369_bib24","series-title":"Pevonedistat as a single agent and in combination with chemotherapy in patients with malignant mesothelioma","year":"2019"},{"issue":"19","key":"10.1016\/j.dmd.2026.100369_bib25","first-page":"4595","article-title":"In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative","volume":"53","author":"Hyafil","year":"1993","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.dmd.2026.100369_bib26","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1158\/0008-5472.CAN-04-1817","article-title":"Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2","volume":"65","author":"Ahmed-Belkacem","year":"2005","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.dmd.2026.100369_bib27","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/0006-291X(91)91647-U","article-title":"Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells","volume":"175","author":"Artursson","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"issue":"17","key":"10.1016\/j.dmd.2026.100369_bib28","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s40265-017-0832-z","article-title":"A review of food-drug interactions on oral drug absorption","volume":"77","author":"Deng","year":"2017","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.dmd.2026.100369_bib29","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1124\/dmd.112.050500","article-title":"Variability in P-glycoprotein inhibitory potency (IC50) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria","volume":"41","author":"Bentz","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100369_bib30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpb.2016.12.027","article-title":"Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays","volume":"114","author":"Lee","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"issue":"27","key":"10.1016\/j.dmd.2026.100369_bib31","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3390\/molecules27061977","article-title":"Development of an LC-MS\/MS method for ARV-110, a PROTAC molecule, and applications to pharmacokinetic studies","volume":"18","author":"Nguyen","year":"2022","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.dmd.2026.100369_bib32","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1021\/acs.jmedchem.3c01007","article-title":"Discovery and preclinical pharmacology of NX-2127, an orally bioavailable degrader of Bruton\u2019s tyrosine kinase with immunomodulatory activity for the treatment of patients with B cell malignancies","volume":"67","author":"Robbins","year":"2024","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.dmd.2026.100369_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.101175","article-title":"Characterization of preclinical radio ADME properties of ARV-471 for predicting human PK using PBPK modeling","volume":"15","author":"He","year":"2025","journal-title":"J Pharm Anal"},{"issue":"13","key":"10.1016\/j.dmd.2026.100369_bib34","doi-asserted-by":"crossref","first-page":"10548","DOI":"10.1021\/acs.jmedchem.3c01823","article-title":"Discovery of KT-413, a targeted protein degrader of IRAK4 and IMiD substrates targeting MYD88 mutant diffuse large b-cell lymphoma","volume":"67","author":"Weiss","year":"2024","journal-title":"J Med Chem"},{"issue":"20","key":"10.1016\/j.dmd.2026.100369_bib35","doi-asserted-by":"crossref","first-page":"18022","DOI":"10.1021\/acs.jmedchem.4c01305","article-title":"Discovery of KT-474\u2500a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases","volume":"67","author":"Zheng","year":"2024","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.dmd.2026.100369_bib36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1021\/mp0499196","article-title":"Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport","volume":"2","author":"Varma","year":"2005","journal-title":"Mol Pharm"},{"issue":"7","key":"10.1016\/j.dmd.2026.100369_bib37","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1023\/A:1016473601633","article-title":"Biopharmaceutics classification system: the scientific basis for biowaiver extensions","volume":"19","author":"Yu","year":"2002","journal-title":"Pharm Res"},{"issue":"15","key":"10.1016\/j.dmd.2026.100369_bib38","doi-asserted-by":"crossref","first-page":"16666","DOI":"10.1021\/acs.jmedchem.5c01497","article-title":"Linker methylation as a strategy to enhance PROTAC oral bioavailability: insights from molecular properties and conformational analysis","volume":"68","author":"Jimenez","year":"2025","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.dmd.2026.100369_bib39","first-page":"1158","article-title":"Revisiting strategies to target ABC transporter-mediated drug resistance in CNS cancer","volume":"22","author":"Amawi","year":"2025","journal-title":"Cancer Biol Med"},{"issue":"1","key":"10.1016\/j.dmd.2026.100369_bib40","article-title":"Application of a high-resolution in vitro human MDR1-MDCK assay and in vivo studies in preclinical species to improve prediction of CNS drug penetration","volume":"10","author":"Jiang","year":"2022","journal-title":"Pharm Res Persp"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:17:53Z","timestamp":1789766273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0090955626006380"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100369","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel in vitro permeability and efflux classification system for proteolysis targeting chimeras","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100369"}}